A recent study suggests that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Research printed in a major health publication shows that while overweight people can lose substantial amounts of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People purchasing these drugs need to be cognizant of the danger of fast weight regain when the treatment concludes," cautioned expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting weight in about 18 months.
Comparing Treatments
The study, which reviewed 37 of studies involving over 9,000 of participants, compared the effects of the injectable medications with conventional dieting.
The team point out that people who lose weight through diet and exercise usually have a slower weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Fast Rebound
Doctors suggest the way of the drugs accounts for the accelerated rebound.
These medications mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating a significant risk."
A Chronic Issue?
Medical guidelines suggest the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, considering the high risk of relapse, the treatment should be considered long-term.
This view is echoed by pharmaceutical companies, who say that the findings "highlight the chronic nature of obesity," akin to managing diseases like diabetes.
Patient Testimonies
Users who have discontinued the medication report a powerful resurgence of hunger.
"It was like something flipping and I was suddenly extremely hungry," described a patient.
The struggle is compounded if individuals have not established sustainable lifestyle or habit modifications during therapy.
Significant Use
Survey data indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is greater among women than males.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Ultimately, experts caution that while these medications are powerful tools for weight loss, they are not a permanent cure and maintained weight loss relies on integrated lifestyle changes.
